Share on StockTwits

BIOLASE (NASDAQ:BIOL) major shareholder Larry N. Feinberg purchased 2,270,836 shares of the stock in a transaction that occurred on Friday, July 18th. The stock was purchased at an average cost of $1.92 per share, with a total value of $4,360,005.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of BIOLASE (NASDAQ:BIOL) traded up 1.44% on Tuesday, hitting $2.12. The stock had a trading volume of 162,297 shares. BIOLASE has a one year low of $1.1451 and a one year high of $3.9287. The stock’s 50-day moving average is $2.01 and its 200-day moving average is $2.36. The company’s market cap is $79.8 million.

BIOLASE (NASDAQ:BIOL) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.05) by $0.06. The company had revenue of $11.50 million for the quarter, compared to the consensus estimate of $13.29 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. The company’s quarterly revenue was down 21.2% on a year-over-year basis. Analysts expect that BIOLASE will post $-0.33 EPS for the current fiscal year.

Separately, analysts at WallachBeth Capital downgraded shares of BIOLASE from a “buy” rating to a “hold” rating in a research note on Tuesday, May 13th. They now have a $2.50 price target on the stock, down previously from $4.00.

BIOLASE, Inc, formerly BIOLASE Technology, Inc is a medical technology company that develops, manufactures and markets lasers, and markets and distributes dental imaging equipment and other related products designed for applications and procedures in dentistry and medicine.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.